[Form 4] Idexx Laboratories Inc Insider Trading Activity

Rhea-AI Filing Summary

M. Anne Szostak, a director of IDEXX Laboratories, reported multiple transactions on 08/22/2025. She exercised a non-qualified stock option to acquire 2,187 shares at an exercise price of $206.62 per share and, on the same date, sold 2,187 shares at a weighted average price of $647.3252 per share. She also reported two gift transactions of 259 shares each: one reducing her direct holdings and one reflecting shares held by related trusts/foundations. Following the reported transactions, the filing shows 2,449 shares held directly and identified indirect interests via a trust and a family foundation.

Positive

• Exercise of non-qualified option fully disclosed: 2,187 shares acquired at $206.62 (08/22/2025)
• Trust/foundation relationships disclosed: Reporting person identifies trustee/settlor roles and nature of indirect ownership

Negative

• Insider sale of 2,187 shares: sold at a weighted average price of $647.3252 (08/22/2025)
• Reduction in direct holdings due to gifts: 259 shares transferred, reflecting movement out of direct ownership

Insights

Securities Analyst

TL;DR: Director exercised options and sold the same number of shares the same day, leaving modest direct and indirect holdings.

The filing documents a routine insider exercise of a non-qualified stock option for 2,187 shares at an exercise price of $206.62 and an immediate sale of 2,187 shares at a weighted average price of $647.3252. The exercise and sale are clearly disclosed and accompanied by small, documented gift transfers of 259 shares to related entities. For investors, this is a clear disclosure of insider liquidity and movement of shares between personal and affiliated accounts; no additional financial metrics or corporate actions are included in the filing.

Corporate Governance Expert

TL;DR: Transactions are standard insider reporting: option exercise, sale, and documented gifts with trustee relationships disclosed.

The report identifies the reporting person as both settlor and trustee of a named trust and trustee of a family foundation, and it discloses the nature of indirect beneficial ownership for those entities. The filing includes an explanation of the weighted average sale price and offers to provide per-price details upon request, meeting disclosure expectations for Section 16 reporting. There are no indications of unusual or undisclosed arrangements in the text provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SZOSTAK M ANNE

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK ME 04092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		M		2,187	A	$206.62	2,449	D
Common Stock	08/22/2025		S		2,187	D	$647.3252(1)	262	D
Common Stock	08/22/2025		G		259	D	$0	1,542	I	Trust of M. Anne Szostak(2)
Common Stock	08/22/2025		G		259	A	$0	259	I	The O'Hanian-Szostak Family Foundation(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right-to-buy)	$206.62	08/22/2025		M			2,187	(4)	05/07/2028	Common Stock	2,187	(5)	0	D

Explanation of Responses:

1. Represents the weighted average price of the shares sold ranging from a low of $647.30 to a high of $647.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

2. The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust.

3. The reporting person is a trustee of The O'Hanian-Szostak Family Foundation ('Foundation') and has power to direct the distribution of assets held by the Foundation.

4. Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event was earlier.

5. Not applicable.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for M. Anne Szostak	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did IDXX director M. Anne Szostak report on 08/22/2025?

She reported an exercise of a non-qualified stock option to acquire 2,187 shares at $206.62, a sale of 2,187 shares at a weighted average price of $647.3252, and two gift transactions of 259 shares each.

How many IDEXX shares does M. Anne Szostak beneficially own after the reported transactions?

The filing shows 2,449 shares beneficially owned directly following the reported transactions and additional indirect interests reported via a trust and a foundation.

What is the nature of the indirect ownership disclosed in the Form 4?

The reporting person states she is the settlor and trustee of the Trust of M. Anne Szostak and a trustee of The O'Hanian-Szostak Family Foundation, and discloses a pecuniary interest in shares held by the Trust.

What price range is associated with the shares sold by the reporting person?

The filing explains the weighted average sale price of $647.3252 represents sales ranging from a low of $647.30 to a high of $647.45 per share.

Was the option grant or exercise described in the filing subject to any vesting schedule?

Yes. The filing explains the option granted vested in one installment on the one-year anniversary of the grant or on the date of the 2019 annual meeting of shareholders, whichever was earlier.